MedTrace Logo

Assessment of VAC-3S Therapeutic Properties When Combined With Standard ART in the Course of HIV-1 Infection

NCT02041247 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2016-06-17

No results posted yet for this study

Summary

The purpose of this study is to evaluate the protective effect of VAC-3S in controlled HIV patients receiving standard of care antiretroviral treatment.

Conditions

Interventions

BIOLOGICAL

VAC-3S

VAC-3S is administered via intra-muscular route in the arm.

Sponsors & Collaborators

  • InnaVirVax

    lead INDUSTRY

Principal Investigators

  • Raphael Ho Tsong Fang, DVM PhD · InnaVirVax

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2015-09-30
Completion
2016-11-30

Countries

  • France
  • Germany
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02041247 on ClinicalTrials.gov